Medipal and Sony Innovation Fund by IGV were among the investors that boosted the liver disease drug developer's latest round to $52.6m.

Belgium-based liver-transplantation drug developer Promethera Biosciences increased its series D round to €47.2m ($52.6m) on Monday, adding €7.5m in a tranche co-led by an investment vehicle for electronics manufacturer Sony.

Sony Innovation Fund by IGV co-led the tranche with venture capital firm Pegasus Tech Ventures, investing alongside medical supplies distributor Medipal Holdings, family office Six Snow and two unnamed private investors.

Trading group Itochu supplied the initial $11.3m before Mitsui & Co Global Investment, a subsidiary of conglomerate Mitsui,…